{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:59Z","timestamp":1776850499433,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>We described the pharmacokinetics of acetylsalicylic acid and salicylic acid in 5\nchildren with prior Kawasaki disease receiving buffered aspirin tablets or intravenous aspirin\nDL-lysine. Oral aspirin is characterized by its longer mean residence time in the body\n(MRT), an indicator for duration of exposure, than intravenous aspirin (1.18 vs. 0.37 h). The\napparent elimination half-life (t(1\/2)) of acetylsalicylic acid was also longer after oral than after\nintravenous administration of aspirin (40 vs. 17 min). The mean absorption time was calculated\nto be as long as 0.8 h. In contrast, the two modes of administration gave virtually\nidentical results regarding MRT of salicylic acid proper and its t(1\/2). After oral administration\nof aspirin, 51% of the dose is absorbed intact as acetylsalicylic acid while 23% is converted to\nsalicylic acid presystemically, indicating that 74% of aspirin is actually absorbed. Our data\nsuggest that an equivalent intravenous aspirin dose to achieve the same salicylic acid concentration\nis about 70% of the oral dose. However, the area under the curve of acetylsalicylic\nacid itself, a more potent cyclooxygenase inhibitor than salicylic acid, would be about 1.5\ntimes higher than that following oral administration. The clinical consequences of this exposure\ndifference remain uncertain.<\/jats:p>","DOI":"10.1159\/000457520","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:32Z","timestamp":1502471312000},"page":"180-186","source":"Crossref","is-referenced-by-count":4,"title":["Disposition of Single-Dose Intravenous and Oral Aspirin in Children"],"prefix":"10.1159","author":[{"given":"Shinya","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuuji","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:46Z","timestamp":1776846886000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457520","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}